Combination therapies
US12208099B2 · kind B2 · utility
0Cited by
9References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 9, 2019 |
| Grant date | Jan 28, 2025 |
| Priority date | — |
| Expiry date | Dec 11, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.